Shionogi & Co. invested in Tokyo-based Restore Vision Inc., a startup developing visual restoration gene therapy via "Chimeric Rhodopsin," a protein-based optical sensor targeting blindness from retinal disorders. This marks Shionogi's first corporate venture capital move in ophthalmology innovation.
Source: phys. Original: https://phys.org/news/2026-04-unveil-ai-driven-coral-reef.html
